If you have been reading about RP-HPLC and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-05-20. Where a claim depends on a specific study, the study is described rather than over-claimed.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; visual inspection |
| Solubility | Soluble in water and aqueous buffers | Depends on pH, purity, and counterion |
| Typical storage | -20 °C or below, desiccated | Protect from light; avoid repeated freeze-thaw after reconstitution |
| Common analytical method | Reversed-phase HPLC and mass spectrometry | Purity by HPLC; identity and mass by LC-MS or MALDI-TOF |
| Common synonyms | hGH fragment 176–191; AOD-9604 | Names vary in research and product labeling |
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
This can be due to any number of factors, including improved nutrition resulting in rapid body growth, increased weight and fat deposition, or exposure to endocrine disruptors such as xenoestrogens, which can at times be due to food consumption or other environmental factors. However, more modern archeological research suggests that the rate of puberty as it occurs now is comparable to other time periods. Growth spurts began at around 10–12, but markers of later stages of puberty such as menarche had delays that correlated with severe environmental conditions such as poverty, poor nutrition, and air pollution. Puberty that starts earlier than usual is known as precocious puberty, and puberty which starts later than usual is known as delayed puberty. Notable among the morphologic changes in size, shape, composition, and functioning of the pubertal body, is the development of secondary sex characteristics, the "filling in" of the child's body; from girl to woman, from boy to man. Derived from the Latin puberatum (age of maturity), the word puberty describes the physical changes to sexual maturation, not the psychosocial and cultural maturation denoted by the term adolescent development in Western culture, wherein adolescence is the period of mental transition from childhood to adulthood, which overlaps much of the body's period of puberty.
The Kokuryūkai was founded in 1901 by martial artist Uchida Ryohei as a successor to his mentor Mitsuru Tōyama's Gen'yōsha. Its name is derived from the translation of the Amur River, which is called Heilongjiang or "Black Dragon River" in Chinese (黑龍江), read as Kokuryū-kō in Japanese. Its public goal was to support efforts to keep the Russian Empire north of the Amur River and out of East Asia. The Kokuryūkai initially made strenuous efforts to distance itself from the criminal elements of its predecessor, the Gen'yōsha. As a result, its membership included cabinet ministers and high-ranking military officers as well as professional intelligence operatives. However, as time passed, it found the use of criminal activities to be a convenient means to an end for many of its operations. The Society published a journal, the Kokuryū Kaiho (Amur Bulletin) and operated an espionage training school, from which it dispatched agents to gather intelligence on Russian activities in Russia, Manchuria, Korea and China. Ikki Kita was sent to China as a special member of the organization. It also pressured Japanese politicians to adopt a strong foreign policy. The Kokuryūkai also supported Pan-Asianism, and lent financial support to revolutionaries such as Sun Yat-sen and Emilio Aguinaldo. During the Russo-Japanese War, annexation of Korea and Siberian Intervention, the Imperial Japanese Army made use of the Kokuryūkai network for espionage, sabotage and assassination.
In medieval Europe, early Christian monasteries adopted Roman aquacultural practices. Aquaculture spread because people away from coasts and big rivers were otherwise dependent on fish which required salting in order to be preserved. Fish was an important food source in medieval Europe, when in average 150 days per year were days of fasting and abstinence, and meat was prohibited. Improvements in transportation during the 19th century made fresh fish easily available and inexpensive, even in inland areas, rendering aquaculture less popular. The 15th-century fishponds of the Trebon Basin in the present-day Czech Republic are maintained as a tentative UNESCO World Heritage Site. Samoans practised "a traditional form of giant clam ranching". Hawaiians constructed oceanic fish ponds. A remarkable example is the "Menehune" fishpond dating from at least 1,000 years ago, at Alekoko. Legend records its construction by the mythical Menehune dwarf-people. In the first half of the 18th century, German Stephan Ludwig Jacobi experimented with external fertilization of brown trout and salmon. He wrote an article "Von der künstlichen Erzeugung der Forellen und Lachse" (On the Artificial Production of Trout and Salmon) summarizing his findings, and earning him a reputation as the founder of artificial fish-rearing. By the latter decades of the 18th century, oyster-farming had begun in estuaries along the Atlantic Coast of North America. The word "aquaculture" appeared in an 1855 newspaper article in reference to the harvesting of ice.
Sources: en.wikipedia.org
The use of MDMA in Texas clubs declined rapidly after criminalization, but by 1991, the drug became popular among young middle-class whites and in nightclubs. In 1985, MDMA use became associated with acid house on the Spanish island of Ibiza. Thereafter, in the late 1980s, the drug spread alongside rave culture to the United Kingdom and then to other European and American cities. Illicit MDMA use became increasingly widespread among young adults in universities and later, in high schools. Since the mid-1990s, MDMA has become the most widely used amphetamine-type drug by college students and teenagers. MDMA became one of the four most widely used illicit drugs in the US, along with cocaine, heroin, and cannabis. According to some estimates as of 2004, only marijuana attracts more first time users in the United States. After MDMA was criminalized, most medical use stopped, although some therapists continued to prescribe the drug illegally. Later, Charles Grob initiated an ascending-dose safety study in healthy volunteers. Subsequent FDA-approved MDMA studies in humans have taken place in the United States in Detroit (Wayne State University), Chicago (University of Chicago), San Francisco (UCSF and California Pacific Medical Center), Baltimore (NIDA–NIH Intramural Program), and South Carolina. Studies have also been conducted in Switzerland (University Hospital of Psychiatry, Zürich), the Netherlands (Maastricht University), and Spain (Universitat Autònoma de Barcelona). "Molly", short for 'molecule', was recognized as a slang term for crystalline or powder MDMA in the 2000s.
== Other developments because of reverse vaccinology and bioinformatics == Reverse vaccinology has caused an increased focus on pathogenic biology. Reverse vaccinology led to the discovery of pili in gram-positive pathogens such as A streptococcus, B streptococcus, and pneumococcus. Previously, all gram-positive bacteria were thought to not have any pili. Reverse vaccinology also led to the discovery of factor G binding protein in meningococcus, which binds to complement factor H in humans. Binding to the complement factor H allows for meningococcus to grow in human blood while blocking alternative pathways. This model does not fit many animal species, which do not have the same complement factor H as humans, indicating differentiation of meningococcus between differing species.
James and Archer John Porter Martin, allowing for the separation of volatile liquid mixtures with components which have similar boiling points. Nonvolatile liquid mixtures could be separated with liquid chromatography, but substances with similar retention times could not be resolved until the invention of high-performance liquid chromatography (HPLC) by Csaba Horváth in 1970. Modern HPLC instruments are capable of detecting and resolving substances whose concentrations are as low as parts per trillion. One of the most important advancements in forensic chemistry came in 1955 with the invention of gas chromatography-mass spectrometry (GC-MS) by Fred McLafferty and Roland Gohlke. The coupling of a gas chromatograph with a mass spectrometer allowed for the identification of a wide range of substances. GC-MS analysis is widely considered the "gold standard" for forensic analysis due to its sensitivity and versatility along with its ability to quantify the amount of substance present. The increase in the sensitivity of instrumentation has advanced to the point that minute impurities within compounds can be detected potentially allowing investigators to trace chemicals to a specific batch and lot from a manufacturer.
Sources: en.wikipedia.org
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.
Mass spectrometry, such as LC-MS or MALDI-TOF, confirms the molecular mass and can reveal sequence-related impurities. Reversed-phase HPLC is used for purity, and peptide mapping or amino acid analysis can support sequence identity. No single method establishes every quality attribute.
No. AOD9604 is a short synthetic fragment of the hGH sequence, not the full 191-amino-acid hormone. It lacks the regions that mediate hGH receptor activation and growth-promoting effects. Products labeled as AOD9604 should not be assumed to have the same properties as hGH.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.